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Abstract Information remains scarce on human development compared to animal models. Here,
we reconstructed human fetal pancreatic differentiation using cell surface markers. We
demonstrate that at 7weeks of development, the glycoprotein 2 (GP2) marks a multipotent cell
population that will differentiate into the acinar, ductal or endocrine lineages. Development
towards the acinar lineage is paralleled by an increase in GP2 expression. Conversely, a subset of
the GP2+ population undergoes endocrine differentiation by down-regulating GP2 and CD142 and
turning on NEUROG3, a marker of endocrine differentiation. Endocrine maturation progresses by
up-regulating SUSD2 and lowering ECAD levels. Finally, in vitro differentiation of pancreatic
endocrine cells derived from human pluripotent stem cells mimics key in vivo events. Our work
paves the way to extend our understanding of the origin of mature human pancreatic cell types
and how such lineage decisions are regulated.
DOI: 10.7554/eLife.27564.001
Introduction
Intensive efforts are currently dedicated towards the development of cell replacement therapies
using cell types derived from human pluripotent stem cells (hPSC). Human insulin-producing beta
cells represent a paradigm for this type of objective. These cells have a major physiological function,
regulating circulating glucose levels by producing and secreting insulin. In patients suffering from
type one diabetes, these cells are destroyed by an autoimmune mechanism, and would thus need to
be replaced (Benthuysen et al., 2016). Beta cell replacement holds immense promises for diabetic
patients and current strategies have reached major milestones (Pagliuca et al., 2014; Russ et al.,
2015; Rezania et al., 2014). However, it is well accepted that a more detailed understanding of
beta cell development in human is required to generate unlimited functional human beta cells
(Johnson, 2016).
The adult pancreas is composed of acinar cells that excrete enzymes into the duodenum through
a ductal tree, and of endocrine cells (approximately 1% of the total pancreatic cells) that are clus-
tered together forming the islets of Langerhans. The endocrine cells secrete hormones such as insu-
lin (beta cells), glucagon (alpha cells) somatostatin (delta cells), pancreatic polypeptide (gamma cells)
and ghrelin (epsilon cells). The pancreas develops from the primitive gut tube that evaginates into a
dorsal and a ventral anlage (Pan and Wright, 2011; Jennings et al., 2015). Multipotent epithelial
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pancreatic progenitors co-expressing the transcription factors PDX1 and NKX6-1 (Nelson et al.,
2007; Cebola et al., 2015) proliferate upon signals (such as FGF10) from the adjacent mesenchyme
(Bhushan et al., 2001) and subsequently differentiate into the acinar, ductal and endocrine lineages.
Endocrine commitment is initially marked by the expression of a basic helix-loop-helix transcription
factor, NEUROG3, and followed by the expression of the mature endocrine markers
(Gradwohl et al., 2000; Gu et al., 2002).
Due to the difficulties associated with procuring staged human fetal tissues and the limited tools
for their analysis, few data on human development is available and the majority of knowledge on tis-
sue development derives from animal models. This also applies to the pancreas (Jennings et al.,
2015) where only a limited number of studies have been performed on human pancreatic develop-
ment. Theses studies demonstrate similarities but also differences between rodent and human pan-
creatic development (Scharfmann et al., 2013; Jennings et al., 2015; Nair and Hebrok, 2015).
Knowledge on human pancreatic development remains limited. More information exists concern-
ing human hematopoietic cell differentiation thanks to the characterization and use of cell surface
antigens that enabled to identify, quantify and purify hematopoietic stem cells and progenitors at
different stages of their development (Eaves, 2015). By mirroring the hematopoietic field, we devel-
oped here an approach where cell surface markers are used to recapitulate the hierarchical sequence
of human pancreatic development. Specifically, we characterized the expression levels of specific
markers at different stages of human pancreatic development corresponding to 7 to 12 weeks of
development (WD). First we purified human pancreatic epithelial cells by selecting cells positive for
the transmembrane glycoprotein EPCAM and by excluding CD45+ hematopoietic and CD31+ endo-
thelial cells. Next we segregated pancreatic epithelial cells into four populations based on the GP2
and CDH1 (ECAD) expression levels. We observed that the expression levels of GP2 and ECAD cor-
relate with acinar, ductal and endocrine functions. By using the additional cell surface markers
CD142 and SUSD2 we further refined endocrine cell differentiation. Finally, our development model
also applies to the in vitro differentiation of hPSCs into pancreatic endocrine cells.
Taken together our work provides a novel approach to study human fetal pancreas development
and bridges the path between in vivo and in vitro differentiation of human pancreatic endocrine
cells.
Results
EPCAM expression is restricted to the epithelium in the human fetal
pancreas
We tested if EPCAM can be used to purify human fetal pancreatic epithelial fraction enriched in pan-
creatic progenitors. CD31 and CD45 were used to exclude endothelial and hematopoietic cells
respectively. Using this combination of antibodies on human fetal pancreatic cells (9.7WD), we
detected three distinct fractions: the CD45+/CD31+ fraction (the endothelial/hematopoietic cells),
the CD45-CD31-EPCAM- fraction, and the CD45-CD31-EPCAM+ fraction (Figure 1A). To unveil
which fraction contained the pancreatic progenitors, we assayed the expression of PDX1 and NKX6-
1. Immunohistochemistry analysis of human fetal pancreatic sections showed that EPCAM+ cells
expressed PDX1 (Figure 1B). FACS analysis demonstrated that PDX1 and NKX6-1 were co-
expressed in the CD45-CD31-EPCAM+ fraction (Figure 1C–E). RT-qPCR analysis on sorted fractions
confirmed that PDX1 and NKX6-1 expressions were restricted to the CD45-CD31-EPCAM+ fraction
(Figure 1F) whereas the CD45-CD31-EPCAM- fraction did not express pancreatic markers and most
likely represent the mesenchymal pancreatic fraction (later referred as population M) (Figure 1A).
These results suggest that a combination of the cell surface markers EPCAM, CD45, and CD31 can
be used to purify the human fetal pancreatic epithelial fraction.
GP2 and ECAD define four populations in the human fetal pancreatic
epithelium that develop sequentially
Recently, GP2 was identified as a novel cell surface marker of the immature pancreatic progenitor
cells derived from hPSC (Ameri et al., 2017). Furthermore, additional data indicate that ECAD levels
are tightly modulated during endocrine differentiation (Gouzi et al., 2011). Therefore, we analyzed
GP2 and ECAD expression levels in the CD45-CD31-EPCAM+ fraction at 9.4WD. GP2 expression in
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Figure 1. EPCAM expression in the human fetal pancreas. (A) The flow cytometry plot represents CD45 and CD31 expression against EPCAM gated on
live human fetal pancreatic cells (9.7WD), n = 9. (B) Immunohistochemistry for PDX1 and EPCAM on pancreatic section (9WD), n = 3. Scale bar = 100
mm. (C–E) Flow cytometry plots of PDX1 and NKX6-1 expression at 9.4WD on CD45+/CD31+ cells (red square), CD45-CD31-EPCAM- cells (TN = triple
negative green square) and CD45-CD31-EPCAM+ cells (blue square). (F) RT-qPCR analysis of PDX1 and NKX6-1 expression on sorted
CD45-CD31-EPCAM+ and TN cells. ND = Not Detected.
DOI: 10.7554/eLife.27564.002
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CD45-CD31- was restricted to the EPCAM+ fraction (Figure 2—figure supplement 1). GP2 and
ECAD expression segregated the CD45-CD31-EPCAM+ fraction into four distinct populations:
GP2hiECAD+ (named GP2hi), GP2+ECAD+ (named GP2+), GP2-ECAD+ (named GP2-), and the GP2-E-
CADlow (named Elow) (Figure 2A). Remarkably, the cell frequencies of the four populations were well
conserved from one pancreas to the other, demonstrating inter-individual homogeneity (Figure 2B).
We assayed the dynamic expression of GP2 and ECAD in the pancreatic epithelial fraction
(CD45-CD31-EPCAM+) during development (from 7WD to 12WD) (Figure 2C). At 7WD the epithelial
fraction was essentially GP2+ (96 ± 1%). From 7WD to 8.4WD, the GP2- population evolves from
2 ± 1% to 34 ± 6% (p<0.05) (Figure 2C,D). Interestingly, from 8.6WD, we detected cells with a lower
ECAD level (Figure 2—figure supplement 2A,B). This Elow population further increased in frequency
from 10 ± 2% at 9.4WD to 18 ± 3% at 12WD (p<0.05) (Figure 2C,D). At 9.4WD, we also detected a
GP2hi population, increasing in frequency during development (3 ± 1% at 9.4WD to 20 ± 5% at
12WD; p<0.05) (Figure 2C,D and Figure 2—figure supplement 2C). Altogether, the temporal and
continuum GP2 and ECAD expression suggest a progeny relationship between specific cell popula-
tions, the GP2+ population would differentiate either into a GP2hi population or into a GP2- popula-
tion that would later decrease its ECAD level to give rise to the Elow population (Figure 2E).
Acinar and endocrine functions segregate within the GP2 and ECAD
populations
To characterize the four epithelial populations described above, we sorted the GP2hi, GP2+, GP2-
and Elow populations and performed global transcriptomic analyses combined with RT-qPCR analy-
ses at 9 and 11WD. As a non-epithelial control, we included the CD45-CD31-EPCAM- fraction (popu-
lation M) (Figure 1A). Due to limitations in cell numbers, the GP2hi population was only sorted at
11WD. Principal component analysis (PCA) on the sorted populations at 9WD revealed three clus-
ters. PC1 separated the epithelial populations (GP2hi, GP2+, GP2- and Elow) from the mesenchymal
fraction (M), while PC2 segregated the Elow population from the GP2hi, GP2+ and GP2- populations
(Figure 3A). Gene Set Enrichment Analysis (GSEA) using Gene Ontology database indicated that
digestion was the most represented biological process in the GP2hi and GP2+ populations while
endocrine functions (insulin and peptide secretion, hormone secretion) were enriched in the Elow
population (Figure 3B, Figure 3—figure supplement 2). Conversely the pancreatic functions
appeared less enriched in the GP2- population. Next, we defined the list of the ‘specific enriched
genes’ per population (Supplementary file 1b-–c and Materials and method section). We compared
the fetal ‘specific enriched genes’ with the RNAseq Single Cell data from human adult pancreas
(Segerstolpe et al., 2016) (Figure 3—figure supplement 3). The GP2hi population displayed 27
enriched genes (p<0.05), 85% being preferentially expressed in the adult acinar cells (Figure 3C,
and Figure 3—figure supplement 3A). In contrast, the Elow population contained 91 (at 9WD) and
34 (at 11WD) differentially expressed genes (p<0.05) that were also enriched (98% and 100% respec-
tively) in the adult endocrine cells (alpha, beta, delta, epsilon or gamma cells) (Figure 3C, and Fig-
ure 3—figure supplement 3B).
We next generated heatmaps based on Gene Ontology lists and selected acinar, ductal and
endocrine genes. By RT-qPCR analyses we confirmed that acinar markers such as CEL, CELA3A and
CTRC were enriched in the GP2+ population at 9WD and in the GP2hi population at 11WD (Fig-
ure 3—figure supplement 2A, Figure 4A). Ductal markers (CFTR, KRT19 and SPP1) were enriched
in the GP2+ and GP2- populations, especially CFTR at 9WD and 11-13WD (Figure 4—figure supple-
ment 1). The Elow populations (9 and 11WD) were enriched with endocrine transcription factors such
as ARX, PAX4, PAX6, NEUROD1, MAFA, MAFB, ISL1 and NKX2.2 and hormones like CHGA, GCG,
GHRL and INS (Figure 3—figure supplement 2B, Figure 4B).
Finally, to define the cell population where endocrine cells first differentiate, we followed the
expression of the endocrine progenitor marker NEUROG3. NEUROG3 was first detected at 8.4WD
in the GP2- population (Figure 4C) prior to the detection of the Elow population (Figure 2C) and
next (9 to 13WD), found enriched in the Elow population (Figure 4C). Thus, our data suggest that the
first human pancreatic endocrine progenitors differentiate in the GP2- population and mature while
decreasing ECAD levels in the Elow population.
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Figure 2. GP2 and ECAD expression in the human fetal pancreatic epithelium. GP2 and ECAD expressions were assayed by flow cytometry during
development. (A) FACS plots display the expression at 9.4WD of CD45 and CD31 against EPCAM (left plot) and GP2 and ECAD gated on
CD45-CD31-EPCAM+ (right plot). n = 4 (B) Cell frequencies of the GP2hi (GP2hiECAD+), GP2+ (GP2+ECAD+), GP2- (GP2-ECAD+) and Elow (GP2-ECADlow)
populations at 9.4WD. n = 4 (mean ±SEM) (C) GP2 and ECAD expressions on fetal pancreases at 7-12WD gated on CD45-CD31-EPCAM+ cells. 7WD
Figure 2 continued on next page
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CD142 and SUSD2 reveal heterogeneity within the GP2- and Elow
populations during development
The GP2- population displayed both duct and endocrine progenitor cells markers suggesting it con-
tains more than one cell type. We therefore sought for additional discriminant markers by scrutiniz-
ing our transcriptomic data. We observed two cell surface markers, CD142 and SUSD2 with
opposite expression patterns: the Elow population expressed lower CD142 and higher SUSD2 mRNA
levels than the GP2+ and GP2- populations (Figure 5A). FACS analyses showed that at 9.4WD, the
GP2hi and GP2+ populations were uniformly CD142+SUSD2-, while the GP2- and Elow populations
were further divided into three subsets: CD142+SUSD2-, CD142-SUSD2- and CD142-SUSD2+
(Figure 5B). Noteworthy, the CD142-SUSD2+ subset was scarce in the GP2- population (6%), but
represented 40% of the Elow population at 9.4WD (Figure 5B). Accordingly, our data reflects the
heterogeneity within the GP2- and Elow populations that is further resolved using CD142 and SUSD2
antibodies.
Next we examined the CD142 and SUSD2 expression patterns in the GP2- and in the Elow popula-
tions during development. At 7WD the majority of the GP2- population was CD142+SUSD2- (95 ±
2%). This frequency gradually decreased to 62 ± 2% at 9.4WD while the frequency of the
CD142-SUSD2- subset increased from 5 ± 2% at 7WD to 43% at 11.3WD p<0.05 (Figure 5C,D). We
detected the first SUSD2+ cells in the GP2-CD142- subset at a low frequency (1%) at 8.4WD
(Figure 5C). The first Elow population was detected at 8.6WD and was divided into CD142+SUSD2-,
CD142-SUSD2- and CD142-SUSD2+ subsets (Figure 2—figure supplement 2A,B and Figure 5—fig-
ure supplement 1). As development progressed the frequency of the ElowCD142-SUSD2+ subset
decreased (from 48 ± 7% at 8.6WD to 10 ± 1% at 12WD; p<0.05), while the frequency of the
ElowCD142-SUSD2- subset increased (from 30 ± 4% at 8.6WD to 79 ± 3% at 12WD; p<0.05)
(Figure 5B,C,E). Our data thus indicate that the first GP2- cells are CD142+. They progress in their
differentiation program by down-regulating CD142, then up-regulating SUSD2 and finally decreas-
ing ECAD levels.
Endocrine progenitors develop in the GP2-CD142-SUSD2- subset and
mature within the ElowSUSD2+ subset
We analyzed the expression pattern of endocrine markers from 8.6WD to 13WD in the three Elow
subsets. The ElowCD142+SUSD2- subset did not express endocrine markers such as CHGA and NEU-
ROG3 (Figure 6—figure supplement 1). At 8.6WD, CHGA, NEUROD1, NKX2-2 and INS were solely
detected in the ElowCD142-SUSD2+ subset (Figure 6A). Interestingly, at 10-12WD, CHGA, NEU-
ROD1 and NKX2-2 expressions were detected both in the ElowCD142-SUSD2+ and the ElowCD142--
SUSD2- subsets while INS was exclusively detected in the ElowCD142-SUSD2- subset (Figure 6B).
Next we assessed NEUROG3 expression in the different subsets. The first NEUROG3+ were
detected in the GP2-CD142- subset at 8.4WD before SUSD2 up-regulation (Figure 6C). From
8.6WD, when the Elow population was first detected NEUROG3 was enriched in the
ElowCD142-SUSD2+ subset (Figure 6C). Our results indicate that endocrine progenitors first appear
Figure 2 continued
n = 2, 8.4WD n = 9, 9.4WD n = 4, 12WD n = 5. (mean ±SEM) (D) Cell frequencies of the GP2hi, GP2+, GP2- and Elow populations at 7-12WD. Cell
frequencies were calculated from three independent experiments for each time point. (E) Scheme that represents the development of GP2hi, GP2+,
GP2- and Elow populations.
DOI: 10.7554/eLife.27564.003
The following source data and figure supplements are available for figure 2:
Source data 1. Cell frequency at 9.4WD by flow cytometry.
DOI: 10.7554/eLife.27564.004
Source data 2. Cell frequency during development.
DOI: 10.7554/eLife.27564.005
Figure supplement 1. Gating strategy for GP2 and ECAD.
DOI: 10.7554/eLife.27564.006
Figure supplement 2. Expression of ECAD and GP2 during development.
DOI: 10.7554/eLife.27564.007
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Figure 3. Transcriptomic analysis of the GP2hi, GP2+, GP2- and Elow populations. (A) PCA map of sorted pancreatic cells (epithelium and mesenchyme).
(B) Top enriched biological processes in each cell population compared to the mesenchyme. Results were obtained with GSEA software using the GO
database. (C) PCA map of epithelial-sorted cells (GP2hi, GP2+, GP2- and Elow populations) from 9 (top map) and 11WD (bottom map). The number of
Figure 3 continued on next page
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in the GP2-CD142-SUSD2- subset and next mature within the ElowCD142-SUSD2+ subset. INS is first
detected in the Elow CD142-SUSD2+ subset and later on in the ElowCD142-SUSD2- subset.
The ElowCD142-SUSD2+ subset predominantly contains endocrine
progenitors
To assess the frequency of cells expressing endocrine progenitor (NEUROG3, NEUROD1, NKX2-2)
and duct (CFTR) markers in the GP2-CD142-SUSD2- and in the ElowCD142-SUSD2+ subsets, we per-
formed single cell RT-qPCR analyses at 9WD. The GP2-CD142-SUSD2- subset was heterogeneous
and composed of 78% CFTR+NEUROG3 cells, 16% NEUROG3+ and 6% CFTR-NEUROG3- cells.
Among the NEUROG3+ , 47% were NEUROD1-NKX2.2-, 43% co-expressed NEUROD1, and 10% co-
expressed NEUROD1 and NKX2.2. Interestingly, 60% of NEUROG3+ were CFTR+ (Figure 6D). Con-
versely, only 2% of the ElowCD142-SUSD2+ subset was CFTR+NEUROG3-, while 74% was
NEUROG3+ and 24% CFTR-NEUROG3-. NEUROG3+ were essentially homogenous as 100%
expressed NEUROD1+ and 83% co-expressed NKX2-2 as well (Figure 6E). Our findings demonstrate
that the majority of the ElowCD142-SUSD2+ subset is NEUROG3+ co-expressing NEUROD1 and
NKX2-2.
Human pluripotent stem cells differentiation into pancreatic endocrine
cells mimics human fetal endocrine cell development
To determine if similar cell populations were present in pancreatic endocrine cells derived from three
hPSCs (SA121 hESC, AD2.1 iPSC, AD3.1 iPSC), these cells were differentiated to the corresponding
stage (stage 5) where significant endocrine induction occurs (Figure 7A). CD142 and ECAD charac-
terized three distinct populations: ECAD+CD142+, ECAD+CD142- and ECADlowCD142- as it is the
case in the human fetal pancreas (9.4WD) (Figure 7B,C). Similar to the human fetal pancreas,
SUSD2+ cells were enriched in the ECADlowCD142- population (Figure 7B,C). Moreover, NEUROG3,
NEUROD1 and NKX2-2 were mainly expressed in the ECADlowCD142-SUSD2+ population as
observed in the human fetal pancreas at 8.6WD (Figures 6A,C and 7D). Finally, from stage 2–5 the
temporal expression pattern of CD142 and ECAD was reminiscent of the ones occurring in the
human fetal pancreas with a sharp decrease of CD142+SUSD2- subsets (from 95 ± 2 of CD142+-
SUSD2- at stage 2 to 23 ± 4 of CD142+SUSD2- subset; p<0.05) (5D and 7E), as was also the case for
SUSD2 expression (Figures 5E and 7F) in the three hPSC lines. To conclude we demonstrate that
pancreatic endocrine cells derived from human pluripotent stem cells appear to go through the
same intermediate developmental stages as observed during in vivo development.
Discussion
In this study, we reconstruct human fetal pancreatic differentiation by combining a specific combina-
tion of cell surface markers. Although a large set of data is available concerning development in
rodent models, there is only limited knowledge on human development. Importantly, while rodent
and human pancreatic development share many similarities, they differ on several aspects
(Scharfmann et al., 2013; Nair and Hebrok, 2015). For example, the global shape and the way islet
cells cluster are different between rodent and human pancreas (Brissova et al., 2005). Moreover,
the expression pattern of major transcription factors crucial for proper pancreas development such
Figure 3 continued
specifically genes enriched in each population in each population (p<0.05) is displayed. PCA maps are displayed in 2D with the three Principal
Components on figure Figure 3—figure supplement 1) and the Gene Ontology lists in Supplementary file 1a.
DOI: 10.7554/eLife.27564.008
The following figure supplements are available for figure 3:
Figure supplement 1. Principal component analysis.
DOI: 10.7554/eLife.27564.009
Figure supplement 2. Heatmaps of genes from GO Biological processes digestion, insulin secretion and pancreas development.
DOI: 10.7554/eLife.27564.010
Figure supplement 3. The GP2hi and Elow populations are enriched in acinar and endocrine markers respectively.
DOI: 10.7554/eLife.27564.011
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Figure 4. Characterization of the GP2hi, GP2+, GP2- and Elow populations. (A,B) Expression of acinar (A) and endocrine (B) markers in the GP2hi, GP2+,
GP2- and Elow populations by global transcriptomic analyses and by RT-qPCR. (C) Expression of NEUROG3 by RT-qPCR in the GP2hi, GP2+, GP2- and M
populations. Heat maps and RT-qPCR are representative of 3 independents experiments. ND = Non Detected. M = CD45-CD31-EPCAM-. *p<0.05,
**p<0.001, t test. (mean ± SEM).
Figure 4 continued on next page
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as NEUROG3, NKX2-2 and PDX1 differ between rodent and human (Villasenor et al., 2008;
Salisbury et al., 2014; Jennings et al., 2013; Sussel et al., 1998; Ohlsson et al., 1993;
Heimberg et al., 2000). As an example, NEUROG3 is expressed in two waves during rodent fetal
pancreatic development (Villasenor et al., 2008) while only a single-phase is observed in human
(Jennings et al., 2013). It can be speculated that the number of differences between rodents and
humans are under-estimated and more will be discovered by studying human pancreatic develop-
ment. This knowledge will be essential to better design protocols to direct pluripotent stem cells
towards functional insulin-producing pancreatic beta cells (Pagliuca et al., 2014; Rezania et al.,
2014; Russ et al., 2015).
Major progress has recently been made in the field of hPSC differentiation and a number of dif-
ferent cell types can be efficiently generated either in vivo following transplantation into immune-
incompetent mice or in vitro under controlled conditions. However, the cells generated in vitro from
hPSC do not seem fully differentiated and in some cases, display a fetal phenotype rather than an
adult one. This is the case for hepatocytes (Baxter et al., 2015), cardiomyocytes (Karakikes et al.,
2015), neurons (Playne and Connor, 2017) and pancreatic beta cells (Hrvatin et al., 2014). These
partial successes could be in part due to the limited knowledge on human cell development. Here,
we specifically designed new approaches to dissect in great detail pancreatic differentiation in
human. We based our study on human fetal pancreases from 7 to 13WD. This developmental period
corresponds to E12.5-E17 in the mouse when pancreatic progenitors first proliferate and next
develop into differentiated cells (Gittes, 2009; Jennings et al., 2015). At 6-7WD, the human pancre-
atic epithelium is mainly composed of PDX1+NKX6-1+ pancreatic progenitors (Cebola et al., 2015;
Riedel et al., 2012) while endocrine cells are extremely rare (Polak et al., 2000; Castaing et al.,
2001). During the following weeks, proliferating epithelial pancreatic progenitors differentiate into
endocrine, acinar and duct cells (Jennings et al., 2013; Capito et al., 2013).
The fetal pancreas is a compound organ composed of epithelial, mesenchymal, endothelial and
hematopoietic cells. We excluded endothelial and hematopoietic cells using CD31 and CD45 anti-
bodies and used the transmembrane glycoprotein EPCAM as a marker to segregate the fetal pan-
creatic epithelium from the mesenchyme. Previous data indicated that EPCAM is expressed during
human fetal life (18-20WD) in the ductal pancreatic epithelium and in developing islet-like cells but
also in the adult human pancreas in duct and islet cells (Cirulli et al., 1998). Based on this previous
report we demonstrated that EPCAM also marks the fetal pancreatic epithelium at earlier develop-
mental stages, between 7 and 12WD. Moreover, we demonstrated that the EPCAM+ compartment
contains PDX1+NKX6-1+ double-positive cells, a hallmark of pancreatic progenitors (Jennings et al.,
2013; Cebola et al., 2015). Our data also indicate that 45% of the EPCAM+ compartment expresses
lower levels of PDX1 and NKX6-1. It would be interesting to determine if these cells are upstream
progenitors of EPCAM+PDX1+NKX6-1+ cells as recently suggested (Ameri et al., 2017). Then we
further segregated the fetal pancreatic epithelium into four distinct populations using the cell sur-
face markers GP2 and ECAD. GP2 is a glycoprotein that is highly enriched in the acinar cells of the
adult pancreas (Hoops and Rindler, 1991; Yu et al., 2004). Limited knowledge is available on GP2
expression during pancreatic development. Very recently, using a model of pluripotent stem cells
differentiation into pancreatic endocrine cells, GP2 was identified as a novel cell surface marker of
human pancreatic progenitors (Ameri et al., 2017). Our ex vivo data further support this claim. First,
we observed that at 7WD, nearly all pancreatic epithelial cells are GP2+. Moreover, as development
proceeds, the frequency of GP2+ cells decreases. Finally, transcriptomic profiling performed at dif-
ferent developmental stages strongly suggests that the GP2+ population can differentiate into endo-
crine and exocrine cells. Collectively, these data indicate that in the early human fetal pancreas, GP2
is indeed a cell surface marker of a multipotent cell population. Although the GP2+ cell population is
multipotent, it is not yet certain if the GP2+ population contains multipotent GP2+ progenitor that
Figure 4 continued
DOI: 10.7554/eLife.27564.012
The following figure supplement is available for figure 4:
Figure supplement 1. Expression of ductal markers in the GP2hi, GP2+, GP2- and Elow populations.
DOI: 10.7554/eLife.27564.013
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Figure 5. Expression of CD142 and SUSD2 in the GP2hi, GP2+, GP2- and Elow populations. (A) Expression of CD142 and SUSD2 in GP2+, GP2- and Elow
populations at 9WD by microarray analysis. Boxplots were obtained using standardized log2 expression values. (B) Expression of CD142 and SUSD2 in
the GP2hi (in green), GP2+ (in red), GP2- (in purple) and Elow (in orange) populations at 9.4WD by flow cytometry. GP2 and ECAD expressions were
gated on live CD45-CD31-EPCAM+ cells. (C) Expression of CD142 and SUSD2 in the GP2+ (left plot), GP2- (right plot) and Elow (far right plot)
Figure 5 continued on next page
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can differentiate into the three lineages (endocrine, acinar and ductal) or represent a mixture of
GP2+ progenitors already committed to a specific lineage. This could be addressed by utilizing a sin-
gle cell culture approach. However, our attempts so far to culture so few cells sorted from human
fetal pancreas have failed. Discovering new and efficient culture conditions such as co-culture on
feeder layers could alleviate this issue (Trott et al., 2017).
In animal models, cell adhesion molecules have emerged as key regulators of embryonic morpho-
genesis and this topic has been extensively studied using pancreatic development as a model organ
(Semb, 2004). As an example, during mouse and chick development, Pdx1+Nkx6.1+ progenitors
express high levels of ECAD. NEUROG3+ endocrine progenitors will develop from such pancreatic
progenitors while lowering their ECAD level during their delamination from the ductal tree to
develop into pancreatic endocrine cells (Gouzi et al., 2011). Information remains scarcer on the reg-
ulation of ECAD levels during human development. Our results indicate that at 7WD, GP2+ pancre-
atic progenitors express ECAD at high levels. At 8.6WD, ECADlow cells appear, their frequency
increasing while development progresses. Interestingly, NEUROG3-expressing cells first appear at
8.4WD in the ECAD+ population and are found later on in the ECADlow population. Whether it is
linked to their delamination remains to be demonstrated. This step is followed (at 8.6WD) by the
expression of endocrine markers such as CHGA, NEUROD1 and INS. Of importance, endocrine cells
expressed low but significant levels of ECAD. This perfectly fits with mouse data that indicate that
during development ECAD function is necessary for proper aggregation of endocrine cells after
delamination (Dahl et al., 1996). Taken together, our data demonstrate that ECAD levels are tightly
regulated during specific steps of human pancreatic development.
We further refined specific pancreatic cell populations by using CD142 and SUSD2 found in our
transcriptomic analysis as additional cell surface markers. CD142 has been proposed as a marker of
pancreatic endodermal cells that also labels additional cell types (Kelly et al., 2011). SUSD2 was
previously used as a marker to enrich NEUROG3+ from hPSC derived pancreatic cells and the human
fetal pancreas (Liu et al., 2014). Here, with our set of markers we reconstructed human pancreatic
cell differentiation (Figure 7G). The full combination of markers was required for this reconstruction
as none of the markers was specific to the different subsets (Figure 7—figure supplement 1). Our
data indicate that GP2+CD142+ pancreatic progenitors can either give rise to GP2hiCD142+ acinar
cells or enter the endocrine pathway and express NEUROG3 by turning off GP2 and CD142. Endo-
crine maturation further progresses by up-regulating SUSD2 and decreasing ECAD level
(Figure 7G). The first INS + cells were detected at 8.6WD in the Elow population as SUSD2+ and later
on as SUSD2-. Recently, differences in gene expression and functionality were observed between
fetal, neonatal and adult beta cells (Hrvatin et al., 2014; Jermendy et al., 2011; Blum et al., 2012).
Moreover, heterogeneity between adult beta cells was also recently described (Dorrell et al., 2016;
Bader et al., 2016). Whether INS + cells positive for SUSD2 represent a first wave of beta cells that
could be poly-hormonal remains to be tested. Moreover, comparative analyses between INS + cells
from ElowSUSD2+ and ElowSUSD2- subsets will define the differences in their transcriptional factor
networks.
FACS-based approaches have been used since the eighties in the hematopoietic field to dissect
hematopoiesis (Spangrude et al., 1988). However, it has rarely been used in the field of pancreatic
development and even less frequently with human fetal pancreases. In the pancreas, the majority of
the cell sorting approaches was performed by analyzing fluorescent signals from tagged proteins
derived from transgenic mice (Gu et al., 2004; Miyatsuka et al., 2014). While highly informative,
this strategy cannot be used to dissect human pancreatic development. Antibodies against cell
Figure 5 continued
populations at 7WD, 8.4WD, and 11.3WD. (D) Cell frequencies of the GP2-CD142+SUSD2- (named CD142+SUSD2- in yellow) and the
GP2-CD142-SUSD2- (CD142-SUSD2- in red) subsets from 7WD to 9.4WD. (mean ± SEM). (E) Cell frequencies of the ElowGP2-CD142-SUSD2+ (named
ElowSUSD2+, in purple) and the ElowGP2-CD142-SUSD2- (ElowSUSD2-, in green) subsets from 7 to 12WD. (mean ± SEM). (A) n = 2–3, (B) n = 3; C) 7WD
n = 2, 8.4WD to 9.4WD n = 3. (D) n = 3.
DOI: 10.7554/eLife.27564.014
The following figure supplement is available for figure 5:
Figure supplement 1. Expression of CD142 and SUSD2 in the GP2+, GP2- and Elow populations at 8.6WD.
DOI: 10.7554/eLife.27564.015
Ramond et al. eLife 2017;6:e27564. DOI: 10.7554/eLife.27564 12 of 22
Research article Developmental Biology and Stem Cells
Figure 6. Molecular characterization of the GP2-CD142-SUSD2- and ElowGP2-CD142-SUSD2- subsets. (A, B) RT-qPCR for CHGA, NEUROD1, NKX2-2 and
INS on sorted GP2-CD142+SUSD2- (GP2-CD142+), GP2-CD142-SUSD2- (GP2-CD142-), ElowGP2-CD142-SUSD2+ (ElowSUSD2+) and ElowGP2-CD142-SUSD2-
(ElowSUSD2-) subsets at 8.6 and 10-12WD. (C) RT-qPCR for NEUROG3 at 8.4, 8.6, 9 and 11-13WD in the GP2-CD142+SUSD2- (GP2-CD142+),
GP2-CD142-SUSD2- (GP2-CD142-), ElowGP2-CD142-SUSD2+ (ElowSUSD2+) and ElowGP2-CD142-SUSD2- (ElowSUSD2-) subsets. (D, E) Single cell RT-qPCR
Figure 6 continued on next page
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surface markers were used in a limited number of studies on pancreas development and mainly in
rodents. It was found that a combination of CD49f and CD133 antibodies can be used to enrich frac-
tion in mouse pancreatic progenitors expressing NEUROG3-expressing cells with some data on
human fetal pancreas. However, the enrichment in NEUROG3 on human fetal pancreas was limited
using this combination of markers (Sugiyama et al., 2007). More recently, SUSD2 was used as a
marker to enrich NEUROG3+ cells in hPSC -derived pancreatic cells and in the human fetal pancreas
(Liu et al., 2014). Our data confirm this point. However our single cell qPCR indicate that SUSD2
does not mark all, but only a subset of NEUROG3+ that co-expressed NEUROD1 and NKX2-2. Thus,
by using a combination of antibodies against cell surface markers, we demonstrate that cell popula-
tions highly enriched in specific functions can be sorted from the human fetal pancreas at different
stages of development, allowing the reconstruction of the differentiation program. Our model con-
stitutes a key advancement in understanding human fetal pancreas development by mapping out
the pattern of differentiation of the three main pancreatic lineages. We further refined our work for
the endocrine pathway by describing for the first time, discrete stages of human pancreatic endo-
crine cell differentiation and showed that our development model also applies to the in vitro differ-
entiation of hPSCs into pancreatic endocrine cells. To the best of our knowledge, this type of side-
by-side comparison that demonstrates that in vitro hPSC differentiation mimics in vivo events has
rarely been done.
In conclusion, we provide a novel way of approaching human pancreatic differentiation. Our work
will be useful to fill the limited knowledge on human pancreas development. It should also pave the
way for developing new cell therapies for diabetic patients.
Materials and methods
Pancreatic dissection and cell suspension preparation
All experiments on human fetal pancreas were performed at INSERM Paris, France. Human fetal pan-
creases were isolated from surgical abortion done by suction aspiration between 7 to 13 weeks of
development (Castaing et al., 2001; Capito et al., 2013; Scharfmann et al., 2014) in compliance
with the French bioethics legislation and the guidelines of our institution. Approval was obtained
from Agence de Biomedecine, the French competent authority along with maternal written consent.
Ages were determined on the basis of time since the last menstrual period and hand and foot mor-
phology. Fetal pancreases were micro dissected with forceps under a binocular magnifying lens,
rinsed with Hanks Balanced Salt Solution (HBSS) from Gibco to remove contaminating blood cells
and gently disrupted using forceps. Afterwards, pancreases were incubated for 5 min in collagenase
V (0.5 mg/ml) (Sigma Aldrich) in HBSS in the presence of calcium and magnesium. Cells were rinsed
in HBSS and then incubated for 5 min in trypsin (0.05%) (Gibco). Finally, cells were rinsed in HBSS
supplemented with 20% Fetal calf serum (from Eurobio). Pluripotent stem cells were washed with
PBS without Ca2+ and Mg2+ (Invitrogen, FRANCE) and incubated with TrypLE select for 1–3 min.
Maintenance and differentiation of human pluripotent stem cell lines
A human ESC (SA121) (Heins et al., 2004) obtained from Takara and two iPSC (SB Ad2.1 and SB3.1)
(van de Bunt et al., 2016) obtained from the StemBANCC consortium were applied for this study.
These cell lines had been confirmed to be pluripotent by evaluation of pluripotency marker expres-
sion, tri-lineage differentiation and karyotyping and tested negative for mycoplasma contamination.
Figure 6 continued
at 9WD on 172 GP2-CD142+SUSD2- (GP2-SUSD2-, left panel) and 166 ElowGP2-CD142-SUSD2+ (SUSD2+, right panel) cells for the expression of PPIA,
NEUROG3, NEUROD1, NKX2-2 and CFTR. Pie charts represent the percentage of NEUROG3+ (in orange), NEUROG3-CFTR+ (in blue) and
NEUROG3-CFTR- cells (in grey). For NEUROG3+ the percentages of NEUROD1+, NKX2-2+, and CFTR+ cells are displayed. Each line represents one
cell. PPIA- cells were excluded from the analysis. (A–C) n = 3, (D, E) n = 2. *p<0.05, ****p<0.0001, t test. (mean ±SEM).
DOI: 10.7554/eLife.27564.016
The following figure supplement is available for figure 6:
Figure supplement 1. Expression of CHGA and NEUROG3 in the ElowCD142+ subsets.
DOI: 10.7554/eLife.27564.017
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Figure 7. Expression of CD142, ECAD and SUSD2 in pancreatic endocrine cells derived from hPSCs. (A) Scheme of in vitro differentiation of hPSCs into
endocrine pancreatic cells. (B, C) Expression of CD142, ECAD (gated on lived CD45-CD31-EPCAM+ cells for the human) and SUSD2 in CD142+, CD142-
and Elow population by flow cytometry in the human fetal pancreas at 9.4WD (in B) and in pancreatic endocrine cells derived from hPSCs (AD3.1 iPSC)
at stage 5 (in C). (D) RT-qPCR on CD142+E-CAD+SUSD2- (named CD142+), CD142-E-CAD+SUSD2- (named CD142-), CD142-E-CADlowSUSD2+ (named
Figure 7 continued on next page
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All three lines were cultured in mTeSR1 medium (StemCell Technologies) on hESC-qualified matrigel
(Corning). Cells were passaged every 3–4 days or when confluent by dissociating to a single cell solu-
tion using TrypLE select (ThermoFisher). Single cells were seeded onto freshly coated Matrigel tissue
culture flask in mTeSR1 containing of 5 uM Tiger (Rock inhibitor, Sigma-Aldrich) and medium was
replenished daily. For differentiation of the hESC/hiPSC lines cells were dissociated to a single cell
solution using TrypLE select and resuspended mTeSR1 with 5 uM Tiger. Cells were seeded at a con-
centration of 0.35  106 cells/cm2 onto growth-factor reduced matrigel CellBIND surfaces (Corning).
Cells were incubated for 24 hr before the start of the differentiation. Differentiation to the pancreatic
lineage was conducted as described in a previously published protocol (Rezania et al., 2014) with
the following modifications: CHIR99201 (Axon Medchem) was applied at 3 uM and 0.3 uM concen-
tration for the first and second day, respectively of the definitive endoderm differentiation instead of
MCX-928 used in the original protocol. MCDB131 medium (Life technologies) was used as basal
medium throughout the differentiation instead of BLAR medium. Cells were not dissociated and
incubated as clusters on air-liquid filters during stage 5; instead cells were kept in 2D cultures
throughout the differentiation.
Flow cytometry
Following dissociation, cells were incubated with antibodies for 20 min in FACS medium (HBSS +2%
FCS), then rinsed in FACS medium and re-suspended in FACS medium with Propidium Iodide (1/
4000) (Sigma Aldrich) or DAPI solution (0,1 ug/ml) (BD Biosciences) to label dead cells. For intra-cel-
lular staining cells were fixed for 5 min in 3% PFA and then rinsed in DPBS from GIBCO. Then cells
were permeabilized in DPBS +3% BSA +0.3% Triton and incubated with antibodies overnight at 4˚C,
rinsed and re-suspended in DPBS. For each antibody, optimal dilution was determined by titration.
The following antibodies were used: anti CD45-PerCP/Cy5.5 (1/20, clone 2D1, Biolegend; RRID: AB_
2566351), anti CD31-PerCP/Cy5.5 (1/20, clone WM59, Biolegend; RRID: AB_2566174), anti-EPCAM-
Brillant violet 605 (1/20, clone 9C4, Biolegend; RRID: AB_2562518), anti ECAD-PE-Cy7 (1/20, clone
67A4, Biolegend; RRID: AB_2563096), anti-GP2-PE (1/5, clone 3G7H9, MBL; RRID: AB_11160953),
anti-SUSD2-VioBrightFITC (1/20, W5C5, Miltenyi Biotec; RRID: AB_2653618), anti-CD142-VioBlue (1/
20, clone HTF-1, Miltenyi Biotec; RRID: AB_2655132), anti-PDX1-alexaFluor 488 (1/20, clone 658A5,
BD Biosciences) and anti-NKX6-1-alexaFluor 647 (1/20, clone R11-560, BD Biosciences). An ARIA III
(BD Bioscience) was used for cell sorting and a FACS LSRFortessa for analysis (BD Bioscience). Data
were analyzed using FlowJo 10.2 software. Dead cells were excluded from analyses performed on
lived cells. Lived cells referred to cells that did no incorporate the dead cell stain Propidium Iodide.
Immunohistochemistry
Human fetal pancreatic sections (4–5 mm thick) were prepared and processed as previously
described (Castaing et al., 2005). The following primary antibodies were used anti-mouse EPCAM
(1:500, clone VU1D9, Cell Signaling) and anti-rabbit PDX1 (1/1000) (Duvillie´ et al., 2003). The sec-
ondary antibodies were anti-mouse Alexa Fluor 488 antibodies (1:400, Life Technologies) and anti-
rabbit Alexa Fluor 594 antibodies (1:400, Jackson ImmunoResearch). The nuclei were stained using
the Hoechst 33342 fluorescent stain (0.3 mg/ml, Invitrogen, France).
Figure 7 continued
ElowSUSD2+), CD142-E-CADlowSUSD2- (named ElowSUSD2-) from hPSCs (AD3.1 iPSC) at stage five for NEUROG3, NEUROD1 and NKX2-2). (E) Cell
frequencies of CD142+SUSD2- (in yellow) and CD142-SUSD2- (in red) from hPSCs (SA121 hESC, AD2.1 iPSC, AD3.1 iPSC) from stage 2–5. (F) Cell
frequencies of ElowSUSD2+ and ElowSUSD2- from hPSCs (SA121 hESC, AD2.1 iPSC, AD3.1 iPSC) from stage 2–5. (G) Scheme representing human
pancreatic differentiation across development using cell surface markers. (B–F) n = 3. *p<0.05, **p<0.001, ***p<0.005, t test.
DOI: 10.7554/eLife.27564.018
The following figure supplement is available for figure 7:
Figure supplement 1. Expression of CD142 and SUSD2 in the mesenchyme, the endothelial/hematopoietic and the epithelial compartments.
DOI: 10.7554/eLife.27564.019
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Bulk and single cells RT-qPCR
For human fetal pancreas, single to 100 cells were sorted in 9 mL of RT/pre-amp mix from the One-
Step qRT-PCR Kit (Invitrogen, France). Pre-amplified (20 cycles) cDNA was obtained according to
manufacturer’s notice and was used for qPCR reaction. The pre-amplified cDNA was then used for
qPCR using the TaqMan protocol. RT, pre-amplification and qPCR were performed using TaqMan
primers from Applied Biosystems. The following TaqMan primers were used: PPIA (Hs04194521_s1),
HPRT1 (Hs99999909_m1), PDX1 (Hs00236830_m1 and Hs00426216_m1), NKX6-1 (Hs00232355_m1),
CEL (Hs01068709_m1), CELA2a (Hs04194660_s1), CELA3A (Hs00371667_gH), CTRC
(Hs00200713_m1), SOX9 (Hs00165814_m1), NEUROG3 (Hs01875204_s1), CHGA (Hs00900370_m1),
NEUROD1 (Hs01922995_s1), INS (Hs02741908), NKX2-2 (Hs00159616_m1). RT-qPCR results are pre-
sented in arbitrary units (AU) relative to expression of the control gene PPIA (for human qPCR) and
HPRT (for hPSC qPCRs). All qPCRs on the human fetal pancreas were assayed using PPIA while
HPRT was used for the qPCR on hPSCs. QPCRs were run on QuantStudio from ThermoFischer and
single cell qPCR were assayed on the Biomark from Fluidigm following manufacture’s instructions.
For human pluripotent stem cell differentiation cells were sorted from three independent differ-
entiations of the ADSB3.1 iPSC line. Cells were lysed in RP1 lysis buffer from the NucleoSpin RNA/
Protein purification kit (Macherey-Nagel) and stored at  80˚C until purification of RNA. RNAs were
extracted using NucleoSpin RNA/protein purification kit. RNA was subsequently converted to cDNA
using iScript cDNA synthesis kit (Biorad) according to manufactures instructions. RT-qPCR was per-
formed on a MX3005P qPCR system (Agilent Genomics) using a fast-2-step protocol (first 95˚C for 1
min, then 40 cycles of 95˚C for 10 s, 60˚C for 25 s). The following TagMan primers were used: NEU-
ROG3 (Hs01875204_s1), NEUROD1 (Hs01922995_s1), NKX2-2 (Hs00159616_m1), bActin
(Hs01060665_g1) and HPRT (Hs99999909_m1).
Global transcriptomic analysis
Total RNA was obtained from Trizol-preserved (Invitrogen, France) sorted cells by chloroform extrac-
tion, quantified and assessed for quality by Agilent-2100 Bioanalyzer (Agilent, Santa Clara, CA).
cDNAs were prepared and amplified using Ovation Pico WTA System V2 kit (NuGEN Technologies,
San Carlos, CA, USA) and hybridized onto GeneChip Human Gene 2.0 ST Array (Affymetrix,Santa
Clara, CA, USA). Quality Control and normalization (RMA) were conducted using Bioconductor Proj-
ect software (https://www.bioconductor.org), which provides log2 transformed expression values.
Data were extracted from raw CEL files using a custom GeneChip library file (CDF file) provided by
http://brainarray.mbni.med.umich.edu/CustomCDF (Dai et al., 2005).
Transcriptomic statistical analysis
Two-sample comparisons were made using two-tailed Student t-test. Transcripts for which any
p-value was above 0.05 were filtered out, leaving 6444 transcripts for further analyses. We compared
expression of these genes in each cell population using Gene Set Enrichment Analysis (GSEA) soft-
ware and the ‘Biological Process’ database of the Gene Ontology Consortium (Subramanian et al.,
2005). Biological processes with FDR q-value <0.05 were considered significant.
Cut off to define the ‘specific enriched genes’:
Each population (GP2hi, GP2+, GP2-, Elow and M) was compared to the other populations using two-
tailed Student t-test. Genes were considered as enriched in a specific population when over-
expressed (p-value<0,05 and Fold Change > 2) in a population compared to any of the others. The
list of the ‘specific enriched genes’ is displayed in supplementary file 1b and c.
Expression pattern of the enriched fetal genes in the adult pancreas:
We use data from the single-cell RNA-seq (Segerstolpe et al., 2016). The normalized data are avail-
able on ArrayExpress (http://www.ebi.ac.uk/arrayexpress/ experiments/E-MTAB-5060). Next, we
generated heatmaps displaying the expression of the fetal ‘specific enriched genes’ in the adult aci-
nar, alpha, beta, epsilon, gamma and ductal cells.
Heatmaps were generated by the ‘heatmap2’ function from gplots R package (https://cran.r-proj-
ect.org/web/packages/gplots/) on standardized log2 expression values, with Pearson correlation as
the distance function.
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Appendix 1
Methods supplementary information
Determination of the developmental stage
Weeks of development (WD) were determined based on the length and the anatomy of the
foot and the hand. We also used the Human Embryo Resource website (https://embryology.
med.unsw.edu.au/embryology/index.php/Embryonic_Development). Then, the precise age
was calculated with the length of the foot and the following formula: Age = 4.11 X Foot
Length + 5.60 (Manjunatha et al., 2012) from the Egyptian Journal of Forensic Sciences).
Replicates
All replicates in this study are biological replicates. The ‘n’ in the figure legends indicates the
numbers of independent biological replicates at each developmental stage. Each flow
cytometry plot displays the results from a single human fetal pancreas. An unpaired
Student’s t-test was performed on the FACS data of Figures 2D, 5D–E and 7E. Below is the
number of independent pancreas analyzed:
. Figure 1A: 9 pancreases at 9.7WD
. Figure 1C-D: 3 pancreases at 9WD
. Figure 2A: 4 pancreases at 9.4WD
. Figure 2C: 2 pancreases at 7WD, 9 pancreases at 8.4WD, 4 pancreases at 9.4WD, 5 pan-
creases at 12WD
. Figure 5B: 3 pancreases at 9.4WD
. Figure 5C: 2 pancreases at 7WD, 3 pancreases at 8.4WD, 3 pancreases at 11.3WD.
. Figure 7B: 3 pancreases at 9.4WD
. Figure 7C: three independent FACS analyses assayed on AD3.1 cell line differentiated until
stage 5 day 1.
. Figure 7E-F: three independent FACS analysis assayed on three different hPSC lines differen-
tiated from stage 2 to 5: SA121 hESC, AD2.1 iPSC, AD3.1 iPSC. Figures display the data
from the three lines.
The variability between individual fetal pancreases at the same WD is displayed in
Figures 2D, 5D–E and 7E–F.
qPCR
All qPCR are from three independent experiments derived from the sorting of three
independent fetal pancreases.
Global transcriptomic analysis
We performed a global transcriptomic analyses on three independent pancreases at 9WD and
three at 11WD.
The following populations were sorted:
. At 9WD: GP2+ (triplicate), GP2- (triplicate), Elow (duplicate) and M (triplicate)
. At 11WD: GP2hi (triplicate), GP2+ (triplicate), GP2- (duplicate), Elow (triplicate) and M
(triplicate)
The third replicate for Elow population at 9WD and GP2- population at 11WD were excluded
due to the poor quality of the RNA.
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